Mundipharma And Egis Partner For Pelmeg In Four CEE Markets
Mundipharma is entering into a partnership with Egis for launching its pegfilgrastim biosimilar treatment in Hungary, Romania, Latvia and Lithuania.
You may also be interested in...
Mundipharma and Samsung Bioepis are undertaking an exclusive commercialization partnership for a portfolio of biosimilars in Hong Kong and Taiwan.
Mundipharma has received a positive opinion from the CHMP for its pegfilgrastim biosimilar. However, the firm would not be drawn on how this version fits into its strategy, given that it already markets its Pelmeg version that it obtained through its acquisition of Cinfa Biotech last year.
Mundipharma has struck a deal with Prestige BioPharma for rights to the Singapore-based firm’s biosimilar trastuzumab in selected European markets.